Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | PRKX | P51817 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958684 | 0.79 | HTT (0.44) | PTK2HTTFGFR1 | |
| SCHEMBL24121744 | 0.79 | HTT (0.44) | PTK2HTTFGFR1 | |
| SCHEMBL4838398 | 0.79 | NOS1 (0.37) | PTK2HTTNOS1 | |
| SCHEMBL8423993 | 0.78 | HTT (0.42) | PTK2HTT | |
| SCHEMBL23703901 | 0.71 | PTK2 (0.33) | PTK2HTTPLK4CHEK1AURKA | |
| SCHEMBL15488747 | 0.68 | PTK2 (0.36) | PTK2HTTNOS1PLK4CHEK1 | |
| SCHEMBL23711614 | 0.68 | PIK3C3 (0.40) | PTK2HTTROCK1 | |
| Oxypurinol SCHEMBL49280 | 0.65 | SMN1; SMN2 (0.38) | HTTCHEK1RETFGFR1LRRK2 | |
| SCHEMBL4840039 | 0.65 | DYRK1A (0.35) | KDR | |
| SCHEMBL5337466 | 0.65 | DYRK1A (0.39) | HTTNOS1CHEK1FGFR1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021148010-A1 | PYRAZOLO HETEROARYL RING COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-2069348-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-7563798-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| EP-2069348-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1942900-A2 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7390890-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2008045266-A2 | PYRAZOLOPYRIMIDIWES AS CYCLIN DEPENDENT KINASE INHIBITOR | SCHERING CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| EP-1023308-B1 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004106341-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, USE OF THE SAME FOR CONTROLLING PATHOGENIC FUNGI, AND AGENTS CONTAINING SAID COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | WO | disclosed |
| US-6803455-B2 | PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-10-12 | — | — | US | disclosed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | PTK2 3836/4885HTT 1391/4885NOS1 4035/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | PTK2 4060/4885HTT 1403/4885NOS1 2491/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | PTK2 220/4885HTT 3154/4885NOS1 4059/4885 |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | CFH, NADK, UGT1A3 | PTK2 3144/4885HTT 888/4885NOS1 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.